Abstract
Hypertrophic cardiomyopathy (HCM) is a primary and usually familial cardiac disorder with heterogeneous expression, unique pathophysiology, and a diverse clinical course. Clinically HCM requires a hypertrophied non-dilated left ventricle without evidence of any other cardiac or systemic disease that could produce the extent of hypertrophy observed. In the vast majority of individual adults dying from HCM, there is cardiomegaly typically in the range of twice the normal heart weight. The characteristic histological features in HCM are the presence of marked myocyte hypertrophy, myofiber disarray, left ventricular outflow tract plaque, intramural coronary abnormalities, and interstitial fibrosis. The pathophysiology of HCM is complex and consists of multiple interrelated abnormalities, including left ventricular outflow tract obstruction, diastolic dysfunction, mitral regurgitation, myocardial ischemia, and arrhythmia. Sudden death is not an uncommon complication of HCM and is often precipitated by exercise. The frequency of sudden death in HCM is up to 1% per year in adults with 2–4% per year in children and adolescents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- HCM:
-
Hypertrophic cardiomyopathy
- MRI:
-
Magnetic resonance imaging
References
Maron BJ, Epstein SE. Hypertrophic cardiomyopathy. Recent observations regarding the specificity of three hallmarks of the disease: asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet. Am J Cardiol. 1980;45(1):141–54. Epub 1980/01/01.
Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20(1):1–8. Epub 1958/01/01.
Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic SUBAORTIC stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation. 1964;30(SUPPL 4):3–119. Epub 1964/11/01.
Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation. 1968;37(5):759–88. Epub 1968/05/01.
Maron BJ, Roberts WC, Edwards JE, McAllister HA Jr, Foley DD, Epstein SE. Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. Am J Cardiol. 1978;41(5):803–10. Epub 1978/05/01.
Maron BJ, Sato N, Roberts WC, Edwards JE, Chandra RS. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum. Comparison of fetuses and infants with and without congenital heart disease and patients with hypertrophic cardiomyopathy. Circulation. 1979;60(3):685–96. Epub 1979/09/01.
St John Sutton MG, Lie JT, Anderson KR, O'Brien PC, Frye RL. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J. 1980;44(4):433–43. Epub 1980/10/01.
Emanuel R, Withers R, O’Brien K. Dominant and recessive modes of inheritance in idiopathic cardiomyopathy. Lancet. 1971;2(7733):1065–7. Epub 1971/11/13.
Hollman A, Goodwin JF, Teare D, Renwick JW. A family with obstructive cardiomyopathy (asymmetrical hypertrophy). Br Heart J. 1960;22:449–56. Epub 1960/09/01.
Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62(5):999–1006. Epub 1990/09/07.
Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116(1):14–8. Epub 2004/01/07.
Codd MB, Sugrue DD, Gersh BJ, Melton LJ 3rd. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. Circulation. 1989;80(3):564–72. Epub 1989/09/01.
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785–9. Epub 1995/08/15.
Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 2009;119(8):1085–92. Epub 2009/02/18.
Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26(7):1699–708. Epub 1995/12/01.
Shah PM, Adelman AG, Wigle ED, Gobel FL, Burchell HB, Hardarson T, et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res. 1974;35(2 suppl II):179–95. Epub 1974/08/01.
Lai ZY, Shih CM, Chang NC, Wang TC. Clinical and morphologic features of hypertrophic cardiomyopathy in elderly patients 85 years or older. Jpn Heart J. 1999;40(2):155–64. Epub 1999/07/27.
Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–55. Epub 2012/08/10.
Roberts WC, Ferrans VJ. Pathologic anatomy of the cardiomyopathies. Idiopathic dilated and hypertrophic types, infiltrative types, and endomyocardial disease with and without eosinophilia. Hum Pathol. 1975;6(3):287–342. Epub 1975/05/01.
Roberts CS, Roberts WC. Hypertrophic cardiomyopathy as a cause of massive cardiomegaly (greater than 1,000 g). Am J Cardiol. 1989;64(18):1209–10. Epub 1989/11/15.
Seggewiss H, Blank C, Pfeiffer B, Rigopoulos A. Hypertrophic cardiomyopathy as a cause of sudden death. Herz. 2009;34(4):305–14. Epub 2009/07/04.
Scholz DG, Kitzman DW, Hagen PT, Ilstrup DM, Edwards WD. Age-related changes in normal human hearts during the first 10 decades of life. Part I (growth): a quantitative anatomic study of 200 specimens from subjects from birth to 19 years old. Mayo Clinic Proc. 1988;63(2):126–36. Epub 1988/02/01.
Maron BJ, Kragel AH, Roberts WC. Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. Br Heart J. 1990;63(5):308–10. Epub 1990/05/01.
Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315(10):610–4. Epub 1986/09/04.
Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol. 1987;60(1):123–9. Epub 1987/07/01.
Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31(17):2111–23. Epub 2010/06/02.
Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle ED, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(4):638–45. Epub 2002/02/19.
Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J. 1976;17(5):611–29. Epub 1976/09/01.
Yamaguchi H, Nishiyama S, Nakanishi S, Nishimura S. Electrocardiographic, echocardiographic and ventriculographic characterization of hypertrophic non-obstructive cardiomyopathy. Eur Heart J. 1983;4(Suppl F):105–19. Epub 1983/11/01.
Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: an introduction to pathology and pathogenesis. Br Heart J. 1994;72(6 Suppl):S2–3. Epub 1994/12/01.
Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation. 1979;59(4):689–706. Epub 1979/04/01.
Davies MJ. The current status of myocardial disarray in hypertrophic cardiomyopathy. Br Heart J. 1984;51(4):361–3. Epub 1984/04/01.
Davies MJ. Hypertrophic cardiomyopathy: one disease or several? Br Heart J. 1990;63(5):263–4. Epub 1990/05/01.
Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation. 1981;63(4):882–94. Epub 1981/04/01.
Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001;88(3):275–9. Epub 2001/07/27.
van der Bel-Kahn J. Muscle fiber disarray in common heart diseases. Am J Cardiol. 1977;40(3):355–64. Epub 1977/09/01.
Fujiwara H, Hoshino T, Yamana K, Fujiwara T, Furuta M, Hamashima Y, et al. Number and size of myocytes and amount of interstitial space in the ventricular septum and in the left ventricular free wall in hypertrophic cardiomyopathy. Am J Cardiol. 1983;52(7):818–23. Epub 1983/10/01.
Unverferth DV, Baker PB, Pearce LI, Lautman J, Roberts WC. Regional myocyte hypertrophy and increased interstitial myocardial fibrosis in hypertrophic cardiomyopathy. Am J Cardiol. 1987;59(9):932–6. Epub 1987/04/15.
Frenzel H, Schwartzkopff B, Reinecke P, Kamino K, Losse B. Evidence for muscle fiber hyperplasia in the septum of patients with hypertrophic obstructive cardiomyopathy (HOCM). Quantitative examination of endomyocardial biopsies (EMCB) and myectomy specimens. Zeitschrift fur Kardiologie. 1987;76(Suppl 3):14–9. Epub 1987/01/01.
Francalanci P, Gallo P, Bernucci P, Silver MD, d'Amati G. The pattern of desmin filaments in myocardial disarray. Hum Pathol. 1995;26(3):262–6. Epub 1995/03/01.
Muraishi A, Kai H, Adachi K, Nishi H, Imaizumi T. Malalignment of the sarcomeric filaments in hypertrophic cardiomyopathy with cardiac myosin heavy chain gene mutation. Heart. 1999;82(5):625–9. Epub 1999/10/20.
Angelini A, Calzolari V, Thiene G, Boffa GM, Valente M, Daliento L, et al. Morphologic spectrum of primary restrictive cardiomyopathy. Am J Cardiol. 1997;80(8):1046–50. Epub 1997/11/14.
Waller TA, Hiser WL, Capehart JE, Roberts WC. Comparison of clinical and morphologic cardiac findings in patients having cardiac transplantation for ischemic cardiomyopathy, idiopathic dilated cardiomyopathy, and dilated hypertrophic cardiomyopathy. Am J Cardiol. 1998;81(7):884–94. Epub 1998/04/29.
Galati G, Leone O, Pasquale F, Olivotto I, Biagini E, Grigioni F, et al. Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical-pathological study of 30 explanted hearts. Circ Heart Fail. 2016;9(9). Epub 2016/09/14.
Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43(12):2260–4. Epub 2004/06/15.
Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):875–87. Epub 2010/07/30.
Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging. 2016;9(12):1392–402. Epub 2016/07/28.
Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8(3):545–57. Epub 1986/09/01.
Krams R, Kofflard MJ, Duncker DJ, Von Birgelen C, Carlier S, Kliffen M, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 1998;97(3):230–3. Epub 1998/02/14.
Litovsky SH, Rose AG. Clinicopathologic heterogeneity in hypertrophic cardiomyopathy with regard to age, asymmetric septal hypertrophy, and concentric hypertrophy beyond the pediatric age group. Arch Pathol Lab Med. 1998;122(5):434–41. Epub 1998/05/21.
Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1998;32(7):1943–50. Epub 1998/12/19.
Tazelaar HD, Billingham ME. The surgical pathology of hypertrophic cardiomyopathy. Arch Pathol Lab Med. 1987;111(3):257–60. Epub 1987/03/01.
Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10):1308–20. Epub 2002/03/12.
Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995;92(7):1680–92. Epub 1995/10/01.
Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108(12):1455–60. Epub 2003/09/04.
Mundhenke M, Schwartzkopff B, Stark P, Schulte HD, Strauer BE. Myocardial collagen type I and impaired left ventricular function under exercise in hypertrophic cardiomyopathy. Thorac Cardiovasc Surg. 2002;50(4):216–22. Epub 2002/08/08.
Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Am J Cardiol. 2010;105(12):1842–3. Epub 2010/06/12.
Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3):220–8. Epub 2009/07/11.
Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124(1):40–7. Epub 2011/06/15.
Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation. 1991;84(3):1188–97. Epub 1991/09/01.
Pelliccia F, Pasceri V, Limongelli G, Autore C, Basso C, Corrado D, et al. Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol. 2017;243:379–84. Epub 2017/07/28.
Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 1996;276(3):199–204. Epub 1996/07/17.
Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003;42(11):1959–63. Epub 2003/12/10.
Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212–8. Epub 2000/12/29.
McKenna WJ. The natural history of hypertrophic cardiomyopathy. Cardiovasc Clin. 1988;19(1):135–48. Epub 1988/01/01.
Spirito P, Bellone P. Natural history of hypertrophic cardiomyopathy. Br Heart J. 1994;72(6 Suppl):S10–2. Epub 1994/12/01.
Roberts WC, Kishel JC, McIntosh CL, Cannon RO 3rd, Maron BJ. Severe mitral or aortic valve regurgitation, or both, requiring valve replacement for infective endocarditis complicating hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19(2):365–71. Epub 1992/02/01.
Maron BJ, Lever H. In defense of antimicrobial prophylaxis for prevention of infective endocarditis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(24):2339–40; author reply 40. Epub 2009/12/05.
Spirito P, Rapezzi C, Bellone P, Betocchi S, Autore C, Conte MR, et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation. 1999;99(16):2132–7. Epub 1999/04/27.
Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association rheumatic fever, endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736–54. Epub 2007/04/21.
Gadler F, Linde C, Juhlin-Dannfeldt A, Ribeiro A, Ryden L. Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1996;27(5):1219–24. Epub 1996/04/01.
Maron BJ, Josephson ME. Long-term consequences of the right ventricular pacing mania of the 1990s for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2014;113(1):191–2. Epub 2013/11/19.
Schonbeck MH, Brunner-La Rocca HP, Vogt PR, Lachat ML, Jenni R, Hess OM, et al. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg. 1998;65(5):1207–14. Epub 1998/05/22.
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761–96. Epub 2011/11/10.
Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470–6. Epub 2005/08/02.
Quinones JA, DeLeon SY, Vitullo DA, Hofstra J, Cziperle DJ, Shenoy KP, et al. Regression of hypertrophic cardiomyopathy after modified Konno procedure. Ann Thorac Surg. 1995;60(5):1250–4. Epub 1995/11/01.
Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation. 1997;95(8):2075–81. Epub 1997/04/15.
Maron BJ, Nichols PF 3rd, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol. 1984;53(8):1087–94. Epub 1984/04/01.
Virmani R, et al. Cardiomyopathy. In: Virmani R, Burke A, Farb A, Atkinson JB, editors. Cardiovascular pathology. 2nd ed. Philadelphia: W.B. Saunders Company; 2001.
Burke A, Virmani R. Histopathological basis of cardiomyopathic disorders. In: Narula J, Virmani R, Ballester M, Carrió I, Westaby S, Frazier O, Willerson JT, editors. Heart failure. Pathogenesis and treatment. London: Martin Dunitz; 2002.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Posttest
Posttest
-
1.
Which of the following percent is representative of the actual incidence of HCM in the general population?
-
A.
0.002%
-
B.
0.02%
-
C.
0.2%
-
D.
2%
-
E.
20%
Answer: C
Comment: Epidemiological studies from several parts of the world report a similar prevalence of LV hypertrophy, the quintessential phenotype of HCM, to be 0.2% in the general population, which is equivalent to at least 600,000 affected individuals in the USA.
-
A.
-
2.
Which of the following is not likely to be detected on gross pathologic examination of HCM?
-
A.
Left atrial dilatation
-
B.
Increased heart weight
-
C.
Ventricular scarring
-
D.
Left ventricular outflow tract plaque
-
E.
Myofiber disarray
Answer: E
Comment: HCM shows left atrial dilatation due to decreased left ventricular compliance, and, in a few cases, coexistence of atrial fibrillation may also result in left atrial dilatation. Scarring of the left ventricle increases as the disease progresses; also intramyocardial vessel thickening may result in left ventricle scarring, which can be grossly identified. In obstructive HCM, left ventricular outflow tract plaque is commonly observed grossly. Although myofibril disarray is observed in almost all cases of HCM, it can only be detected by histologic sectioning and staining following dehydration and embedding the ventricular septum from the heart in paraffin.
-
A.
-
3.
Which of the following is characteristic of apical HCM?
-
A.
Atrioventricular block
-
B.
Type III in echocardiographic Maron’s classification
-
C.
High prevalence in Japanese
-
D.
Basal septal thinning
-
E.
High prevalence in Caucasian
Answer: C
Comment: Apical HCM is a rare variant of HCM which shows hypertrophy predominantly in the left ventricular apex. Apical aneurysm and ventricular tachyarrhythmias are observed in several cases. Even though apical HCM constitutes 13–25% of all cases of HCM in Japan, it is much less often observed in non-Japanese populations. This rare variant is not mentioned in Maron’s original classification.
-
A.
-
4.
Which of the following is not a feature of HCM?
-
A.
Endocardial fibrosis on opposite site of the mitral posterior leaflet
-
B.
Left ventricular outflow tract plaque
-
C.
Subaortic stenosis
-
D.
Mitral valve elongation
-
E.
Enlargement of myocyte size
Answer: A
Comment: The frequency of a left ventricular outflow tract plaque is up to 73% in HCM patients. Furthermore, the frequency is 95% in patients with documented subaortic stenosis by catheterization. Endocardial fibrosis and mitral valve thickening and elongation are frequently observed; however, fibrosis of the ventricular septum in the LVOT is observed where the anterior leaflet hits the septum in systole. Enlargement of myocyte size is a typical finding on microscopic examination.
-
A.
-
5.
Which of the following is the least likely detected on histological examination of hearts with HCM?
-
A.
Hyperchromatic nuclei of myocyte
-
B.
Fibroblast disorganization
-
C.
Interstitial fibrosis
-
D.
Bizarre shape of mycytes
-
E.
Intramural coronary thickening
Answer: B
Comment: The characteristic histological features in HCM are the presence of marked myofiber disarray (also called myocyte disarray, myocardial disarray, and myocyte disorganization); myocyte hypertrophy, interstitial fibrosis, and intramural coronary artery thickening with severe narrowing have all been described in HCM hearts. Myocytes show hypertrophy with increase in transverse diameter, and the myocyte nuclei appear hyperchromatic and assume bizarre shapes. Fibroblast disorganization is not a feature of HCM.
-
A.
-
6.
Which of the following modalities is the most likely to detect mycardial fibrosis in HCM?
-
A.
Cardiac computed tomography
-
B.
Echocardiography
-
C.
Cardiac scintigraphy
-
D.
Left ventriculography
-
E.
Contrast-enhanced cardiac MRI
Answer: E
Comment: Delayed contrast-enhanced cardiac MRI is a well-recognized modality to detect areas of cardiac fibrosis in HCM. Several studies reported that the amount of fibrotic areas assessed by cardiac MRI can predict prognosis in patient with HCM.
-
A.
-
7.
Which of the following is a characteristic of late complication accompanying HCM?
-
A.
Mitral valve stenosis
-
B.
Pericardial calcification
-
C.
Thinning of ventricular basal septum
-
D.
Left ventricular dilation
-
E.
Aneurysmal coronary artery
Answer: D
Comment: Complications of hypertrophic cardiomyopathy are listed at Table 3.2. Left ventricular dilatation is a common manifestation of end-stage HCM which is accompanied by extensive myocardial fibrosis.
-
A.
-
8.
Which vessels in HCM demonstrate abnormal vascular wall thickening?
-
A.
Ascending aorta
-
B.
Epicardial coronary arteries
-
C.
Intramural coronary arteries
-
D.
Capillary vessel
-
E.
Coronary sinus
Answer: C
Comment: Intramural coronary artery thickening is present in the ventricular septum in 83% of HCM, and the location correlates well with areas of myofiber disarray. Intramural coronary artery thickening is more common in hearts with fibrosis than those without significant fibrosis.
-
A.
-
9.
Which of the following is not a characteristic of HCM when evaluated by echocardiography?
-
A.
Asymmetric hypertrophy
-
B.
Granular sparkling sign
-
C.
Ground-glass appearance
-
D.
Small ventricular cavity
-
E.
Systolic anterior motion
Answer: B
Comment: Echocardiographically, the hallmarks of HCM include left ventricular hypertrophy, a small ventricular cavity, systolic anterior motion of the anterior leaflet of the mitral valve, and a characteristic ground-glass appearance of the myocardium. Asymmetric hypertrophy is typical, occurring in 80–98% of cases. Granular sparkling sign is the typical feature of cardiac amyloidosis on echocardiography.
-
A.
-
10.
Which of the following is not a risk factor for SCD in HCM patients?
-
A.
Family history of sudden death due to HCM
-
B.
Hypertensive blood pressure response to exercise
-
C.
Unexplained recent syncope
-
D.
Left ventricular apical aneurysm and scarring
-
E.
Extensive and diffuse late gadolinium enhancement
Answer: B
Comment: Risk factors for SCD are listed in Table 3.6. Hypotensive or attenuated blood pressure response to exercise, mainly caused by the LVOT subaortic stenosis, is one of the risk factors of SCD in HCM.
-
A.
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Sakamoto, A., Yahagi, K., Romero, M., Virmani, R. (2019). Pathology and Pathophysiology. In: Naidu, S. (eds) Hypertrophic Cardiomyopathy. Springer, Cham. https://doi.org/10.1007/978-3-319-92423-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-92423-6_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92422-9
Online ISBN: 978-3-319-92423-6
eBook Packages: MedicineMedicine (R0)